Central nervous system toxicity associated with ertapenem use

Annals of Pharmacotherapy

Volumn 45, Issue 1, 2011, Pages

  Duquaine, Susan ^a   Kitchell, Ellen ^b   Tate, Temeka ^c   Tannen, Richard C ^d   Wickremasinghe, Itala Manosha ^a,e  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Global Rehabilitation Hospital   (United States)

^d Pulmonologist   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adverse effects; Antibacterial agents; B lactams; Delirium; Drug tOxicityc; Ertapenem

Indexed keywords

BACLOFEN; CEFAZOLIN; CLAVULANATE POTASSIUM PLUS TICARCILLIN; ERTAPENEM; IMIPENEM; PENICILLIN G;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; DRUG WITHDRAWAL; ELDERLY CARE; HUMAN; INTUBATION; KIDNEY FUNCTION; LABORATORY TEST; MALE; MENTAL HEALTH; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; STROKE;

AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BETA-LACTAMS; CENTRAL NERVOUS SYSTEM DISEASES; DELIRIUM; DRUG MONITORING; HUMANS; LANGUAGE DISORDERS; MALE; MIOSIS; OSTEOMYELITIS; POSTOPERATIVE COMPLICATIONS; STROKE; TREATMENT OUTCOME;

EID: 78751505435     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P528     Document Type: Article

References (9)

1. Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK- 0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001;45:1860-7.
2. Graham D, Lucasti C, Malafaia O, et al. Once a day ertapenem versus four daily doses of piperacillin/tazobactam for treatment of complicated skin and skin structure infections in adults: results of a prospective randomized double-blind multicenter study. Clin Infect Dis 2002;34:1460-8.
3. Teppler H, Gesser RM, Friedland IR, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004;53(suppl 2):ii75-81.
4. Product information. Invanz IV, IM injection (ertapenem IV, IM injection). Whitehouse Station, NJ: Merck & Co., Inc., March 2010.
5. Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005;24:649-53.
6. Norrby SR. Neurotoxicity of carbapenem antibacterials. Drug Saf 1996; 15:87-90.
7. Kong V, Beckert L, Awunor-Renner C. A case of beta lactam-induced visual hallucination. N Z Med J 2009;122:76-7.
8. Campise M. Neurological complication during imipenem/cilastatin therapy in uraemic patients. Nephrol Dial Transplant 1988;13:1895-6.
9. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)